Shengjia Shi

1.4k citations
25 papers · 944 indexed · h-index 13
Topics
Prostate Cancer Treatment and Research (6 papers)Cancer-related molecular mechanisms research (4 papers)RNA Research and Splicing (4 papers)
Partner nations
ChinaUnited States

In The Last Decade

Shengjia Shi

24 papers receiving 938 citations

Peers

Shengjia Shi
Comparison fields: 5 of 75
  • Molecular Biology 448
  • Cancer Research 391
  • Oncology 256
  • Immunology 211
  • Pulmonary and Respiratory Medicine 162
Replace Magali Castells with:
Magali Castells France
Xiaocheng Zhou China
Lucia D’Amico Italy
Minsuk Kwon South Korea
Murat Serilmez Türkiye
Zengli Liu China
Ming-Heng Wu Taiwan
Benjamin Wolfson United States
Shengjia Shi relative to Magali Castells France Magali Castells's profile →
Citations per field
00.5×1.5×2.4×
Magali Castells · 1×
Citations per year

Countries citing papers authored by Shengjia Shi

Since Specialization
Citations

This map shows the geographic impact of Shengjia Shi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shengjia Shi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shengjia Shi more than expected).

Fields of papers citing papers by Shengjia Shi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shengjia Shi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shengjia Shi. The network helps show where Shengjia Shi may publish in the future.

Co-authorship network of co-authors of Shengjia Shi

This figure shows the co-authorship network connecting the top 25 collaborators of Shengjia Shi. A scholar is included among the top collaborators of Shengjia Shi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shengjia Shi. Shengjia Shi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 3
3 1
4 12
5 11
6 11
7 18
8 9
9 20
10 26
11 3
12 10
13 57
14 44
15 17
16 55
17
[miR-590-5p inhibits A375 cell invasion and migration in malignant melanoma by directly inhibiting YAP1 expression].
4
18 271
19 80
20 149

About Shengjia Shi

Shengjia Shi is a scholar working on Cancer Research, Reproductive Medicine and Immunology and Allergy, having authored 25 papers that have together received 944 indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (6 papers), Cancer-related molecular mechanisms research (4 papers) and RNA Research and Splicing (4 papers). The work is most often cited by research in Cancer Research (391 citations), Immunology (211 citations) and Oncology (256 citations). Shengjia Shi has collaborated with scholars based in China and United States. Frequent co-authors include Lijuan Wang, Weihong Wen, Yunhui Li, Yong Jin, Bo Yu, Angang Yang, Zhangyan Guo, Ming Wei, Donghui Han and Yan–Ling Meng. Their work appears in journals such as PLoS ONE, Cancer Research and Scientific Reports.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026